Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Portfolio expansion solidifies company's commitment to advancing cancer research and patient care BURLINGTON, N.C. , April 8, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C. , April 5, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing BURLINGTON, N.C. , April 2, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Transaction to enhance Labcorp's laboratory services network  and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ --  Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO

Labcorp to Announce First Quarter Financial Results on April 25, 2024

BURLINGTON, N.C. , March 27, 2024 /PRNewswire/ --  Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024 .

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care  BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO

Labcorp Launches Weight Loss Management Testing Solutions

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C. , March 7, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services,

Use of liquid biopsy analysis to identify biomarkers related to solid tumors: Insights from a recent Japan symposium (Part 2)

Liquid biopsy analysis offers a promising, minimally invasive approach to detecting and monitoring cancer. It involves the analysis of tumor components like DNA, cells and exosomes found in body fluids. Unlike traditional tissue biopsies, liquid biopsies allow for repeated sampling to track tumor evolution and response to therapy in real time. In his presentation at the recent Japan Symposium 2023, Dr. Sriram Ramanan, associate director of oncology biomarkers at Labcorp’s Biomarker Solution Center, discusses the advantages and disadvantages of using liquid biopsy analysis to identify biomarkers related to solid tumors.

Labcorp Announces 2023 Fourth Quarter and Full Year Results

Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion ; Full year of $12.16 billion vs $11.86 billion Diluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94 Adjusted EPS: Q4